Related references
Note: Only part of the references are listed.Antiphospholipid syndrome, the best prophet of the future
Olga Amengual et al.
MODERN RHEUMATOLOGY (2018)
Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study
R. Hisada et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances
Savino Sciascia et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Maria Luisa Lozano et al.
ANNALS OF HEMATOLOGY (2016)
Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis
Guillaume Moulis et al.
AUTOIMMUNITY REVIEWS (2016)
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
Tomas Jose Gonzalez-Lopez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Adverse effects of glucocorticoids: coagulopathy
Maria Caroline Alves Coelho et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim
Douglas B. Cines et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials
Ferran Catala-Lopez et al.
MEDICINA CLINICA (2015)
Increased Risk of Hemorrhagic and Ischemic Strokes in Patients With Splenic Injury and Splenectomy A Nationwide Cohort Study
Jiun-Nong Lin et al.
MEDICINE (2015)
The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome
Bahar Artim-Esen et al.
CURRENT RHEUMATOLOGY REPORTS (2015)
Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus
M-C Maroun et al.
LUPUS (2015)
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors
M. Ruggeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Use of Oral Glucocorticoids and the Risk of Pulmonary Embolism A Population-Based Case-Control Study
Danka J. E. Stuijver et al.
CHEST (2013)
Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity
Soo Young Kim et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
Bahareh Ghadaki et al.
TRANSFUSION (2013)
Use of Glucocorticoids and Risk of Venous Thromboembolism A Nationwide Population-Based Case-Control Study
Sigrun A. Johannesdottir et al.
JAMA INTERNAL MEDICINE (2013)
Prednisolone exerts exquisite inhibitory properties on platelet functions
Elisabetta Liverani et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng et al.
LANCET (2011)
Clinical Implications of Elevated Antiphospholipid Antibodies in Adult Patients with Primary Immune Thrombocytopenia
Young-Joon Yang et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2011)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study
R. W. Thomsen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Antiphospholipid syndrome
Guillermo Ruiz-Irastorza et al.
LANCET (2010)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
The hematologic manifestations of the antiphospholipid syndrome
Imad Uthman et al.
BLOOD REVIEWS (2008)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
T. Hereng et al.
LUPUS (2008)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis
T Atsumi et al.
LUPUS (2005)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides
P Coppo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura:: a prospective cohort study
R Diz-Küçükkaya et al.
BLOOD (2001)